

# Global Prenatal & Maternal Diagnostic Market To 2020

<https://marketpublishers.com/r/GC135016CA4EN.html>

Date: December 2015

Pages: 359

Price: US\$ 3,800.00 (Single User License)

ID: GC135016CA4EN

## Abstracts

Prenatal tests (fetus, embryos and newborns) currently on the market analyze chromosomes, DNA, RNA, genes, and/or gene products to determine whether an abnormality is present that is causative of a specific disease. Since 2011, the launch of noninvasive prenatal tests (NIPTs) is revolutionizing the prenatal screening industry providing detection rates of >99% and false positive rates of 0.1%. These screening results are only indicative of the risk and not confirmative. To confirm positive results of NIPT screening tests, prenatal diagnostic tests such as amniocentesis and chorionic villus sampling (CVS) are performed. Prior to NIPTs, ultrasound and maternal serum tests were routinely used to screen fetusus for genetic abnormalities.

Globally, 50 countries have effective newborn genetic test programs, the implementation of which is in various stages. In the U.S., four million newborns are tested annually, with 3,000 found to have metabolic and genetic diseases. The purpose of newborn screening is to identify affected newborns quickly and provide them with treatment to prevent mental retardation, prolonged illness and death. The newborn genetic screening market is crowded with different technologies, the common being tandem mass spectrometry, pulse oximetry, enzyme-based assays, DNA assays and electrophoresis.

Preimplantation genetic screening and preimplantation genetic diagnosis (PGS/PGD) are genetic tests performed in eight-celled embryos before implantation during in vitro fertilization (IVF) for the detection of genetic abnormalities and sex. These tests can detect and diagnose chromosomal rearrangements, X-linked diseases and help in reducing the incidence of spontaneous abortions, increase implantation rates, prevent trisomic offsprings and avoid the risk of transmitting single gene disorders. However, PGS and PGD results are not 100% accurate and after pregnancy, if required the diagnostic tests such as amniocentesis and CVS are to be performed to confirm the positive results of PGS/PGD. In the U.S. alone, more than 63,000 babies were born

through IVF in 2013 and compared to 2012 data; it was an increase of 2,000 births.

The most important development in the field of prenatal screening, is the introduction of NIPTs using cell-free fetal DNA (cffDNA) in 2011. Obstetricians and patients who are deterred by the 10% to 15% false positive rates of ultrasound screening and 5% false positive rates of maternal serum tests are eagerly embracing NIPTs which claim to have only 0.1% of false positive results.

Within just four years, molecular genetics firms have successfully produced eight different types of kits for the detection of genetic abnormalities in the fetus. These products have been gradually marginalizing the maternal serum tests and in another decade, maternal serum tests are expected to become obsolete. If, companies can develop NIPTs with a 100% accuracy rate, maternal serum tests, amniocentesis and CVS will all be completely overshadowed by NIPTs. Despite the growing popularity of NIPTs, maternal serum tests still continue to have some market due to their low price. While the maternal serum tests are available for just \$x to \$x, NIPTs are priced between \$x and \$x. However, Sequenom reportedly sold over x tests in 2013 and so pricing does not seem to be a deterrent factor. The introduction of technologies such as digital PCR and next-generation sequencing (NGS) or massively parallel sequencing (MPS) have also enabled accurate estimation of very small differences in chromosome-specific sequences in maternal blood.

The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos. The global prenatal and maternal diagnostic test market is assessed with respect to:

Fetal Ultrasound

Prenatal MRI Screening

Maternal Serum Screening Tests

Noninvasive Prenatal Tests (NIPTs) using cffDNA

NIPTs by Product

Prenatal Diagnostic Invasive Tests

Newborn Screening for Genetic Diseases

Newborn Screening Market by Technology

Preimplantation Screening/Diagnosis (PGS/PGD)

SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets.

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:

Molecular Diagnostics Market

Liquid Biopsy Market

Personalized Medicine Diagnostics Market

In vitro Diagnostics (IVD) Market

This is a comprehensive 359 page report strengthened with over 260 figures and tables. Published in January 2016, the GLOBAL PRENATAL & MATERNAL DIAGNOSTIC MARKET TO 2020 report by KellySciPub has a detailed overview of 114 companies in the market with specifics pertaining to financial and business strategy, current products on the market and pipeline products.

Key Questions Answered in this Report

What are the major prenatal pregnancy complications?

What are the major genetic diseases detected in fetuses?

What are the appropriate technologies for the detection of aneuploidies, microdeletions, duplications, copy number variations and translocations?

How far is genetic counseling important in educating pregnant women and healthcare professionals?

What is the impact of recent advances in clinical genomics on genetic counseling?

What different noninvasive and invasive prenatal screening tests are performed during a pregnancy?

What are the detection rate, true positive rate and true negative rate for NIPTs?

Currently, in which countries are the NIPTs available?

What is the cost of NIPTs region-wise?

What is the uptake of conventional maternal serum tests, NIPTs and invasive diagnostic tests in the U.S.?

What is the average cost of maternal serum screening, NIPTs, fetal ultrasound screening and invasive diagnostic tests in the U.S.?

What are the strategies to be adopted for clinical implementation of NIPTs for all pregnancies?

What is the “patient directed model” for the integration of NIPTs into healthcare systems?

How does the detection rate of NIPTs compare with the rates of conventional maternal serum screening tests?

What are the genetic disorders detectable by different prenatal screening and diagnostic tests?

What is the reliability of amniocentesis and CVS results?

Is the future of invasive diagnostic tests uncertain?

Do the intact fetal cells in maternal blood have use in noninvasive prenatal diagnosis (NIPD)?

What about the use of trophoblast cells obtained from cervix in NIPD?

How many genetic conditions are detected during newborn genetic screening in the U.S.?

What is the status of newborn genetic screening in developed, developing and other countries?

What are the different preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD)?

What are the currently available PGS/PGD testing products available in the market?

What are the currently used advanced technologies in prenatal, newborn and PGD testing?

What is the global market for fetal ultrasound screening, through 2021?

Who are the market leaders in fetal ultrasound systems?

What is the global and regional market for prenatal screening by fetal MRI, through 2021?

What is the global and regional market for maternal screening tests, through 2021?

What is the global and regional market for NIPTs using cffDNA, through 2021?

What is the global and regional market for invasive prenatal diagnostic tests, through 2021?

What is the global and regional market for newborn screening tests, through 2021?

What is the global market for newborn screening tests by technology, through 2021?

What is the global and regional market for pre-implantation genetic diagnosis (PGD), through 2021?

What is the global market for molecular diagnostics, through 2021?

What is the global market for liquid biopsy tests, through 2021?

What is the overall global market for personalized medicine diagnostics, through 2021?

What is the overall global market for in vitro diagnostics (IVD), through 2021?

What are the recent acquisition activities in prenatal screening industry?

What are the important factors that drive the growth of prenatal & newborn genetic testing industry?

What are the challenges faced by the prenatal screening industry?

What are the possible future developments in prenatal screening industry?

## Contents

### 1. INTRODUCTION

- 1.1 Executive Summary
- 1.2 Objectives of this Report
- 1.3 Key Questions Answered in this Report

### 2. PRENATAL PREGNANCY COMPLICATIONS: AN OVERVIEW

#### 2.1 Advanced Maternal Age (AMA)

- 2.1.1 Risk of Down Syndrome with Increased AMA
- 2.1.2 Risk of Miscarriage with Increased AMA
- 2.1.3 Risk of Cesarean Section with Increasing AMA
- 2.1.4 Risk of Gestational Diabetes with AMA
- 2.1.5 Risk for Pregnancy-Induced Hypertension with AMA
- 2.1.6 Risk of Placenta Previa with AMA
- 2.1.7 Delayed First Pregnancy in the U.S.

- 2.1.7.1 First Birth Rates for 35-39 Aged U.S. Women by Race

#### 2.2 Pre-Existing Maternal Medical Conditions

- 2.2.1 Pregnancy Outcome in Women with Renal Disease
- 2.2.2 Pregnancy Outcome in Diabetic Women
- 2.2.3 Pregnancy Outcome in Women with Pre-Existing Thyroid Disease
- 2.2.4 Pregnancy Outcome in Obese Women
- 2.2.5 Pregnancy Outcome in Asthmatic Women
- 2.2.6 Pregnancy Outcome in Women with Epilepsy
- 2.2.7 Pregnancy Outcome in Women with Autoimmune Diseases
- 2.2.8 Pregnancy Outcome in Women with Hemoglobinopathies
- 2.2.9 Pre-Existing Chronic Diseases among Women of Reproductive Ages in the U.S.

- 2.2.9.1 Chronic Disease Risk Behaviors and Risk Factors among Women of Reproductive Ages in the U.S.

#### 2.3 Medical Conditions Occurring During Pregnancy

- 2.3.1 Preeclampsia (Toxemia)
  - 2.3.1.1 Prevalence of Preeclampsia in the U.S.
- 2.3.2 Gestational Diabetes in the U.S.
  - 2.3.2.1 Prevalence of Gestational Diabetes in the U.S.

#### 2.4 Pregnancy-Related Issues

- 2.4.1 Premature Labor
  - 2.4.1.1 Common Medical Complications in Premature Babies

- 2.4.1.2 Global Prevalence of Preterm Labor
- 2.4.1.3 Prevalence of Preterm Births in the U.S. by Stage
- 2.4.1.4 Prevalence of Preterm Births in the U.S. by Race/Ethnicity
- 2.4.1.5 Prevalence of Preterm Births in the U.S. by Plurality of Birth
- 2.4.1.6 Prevalence of Preterm Births in the U.S. by Maternal Age
- 2.4.1.7 Multiple Births in the U.S.
- 2.4.2 Placenta Previa
- 2.4.3 Breech Presentation
- 2.4.4 Meconium Stained Liquor
- 2.4.5 Oligohydramnios and Polyhydramnios
- 2.5 Fetal Problems
  - 2.5.1 Fetal Growth Restriction
  - 2.5.2 Imperforate Anus
  - 2.5.3 Congenital Heart Disease

### **3. TYPES OF GENETIC DISEASES IN FETUSES: AN OVERVIEW**

- 3.1 Single Gene Disorders
  - 3.1.1 Autosomal Dominant Genetic Disorders
    - 3.1.1.1 Huntington Disease (HD)
    - 3.1.1.2 Familial Hypercholesterolaemia (FH)
    - 3.1.1.3 Marfan syndrome
    - 3.1.1.4 Myotonic Dystrophy
  - 3.1.2 Autosomal Recessive Genetic Disorders
    - 3.1.2.1 Cystic Fibrosis (CF)
    - 3.1.2.2 Canavan Disease
    - 3.1.2.3 Neutropenia
    - 3.1.2.4 Ellis-van Creveld Syndrome (EVC)
    - 3.1.2.5 Familial Mediterranean fever (FMF)
    - 3.1.2.6 Faconi Anemia (FA)
    - 3.1.2.7 Gaucher Disease
    - 3.1.2.8 Mucopolysaccharidosis (MPSs)
    - 3.1.2.9 Phenylketonuria (PKU)
    - 3.1.2.10 Sickle Cell Disease
    - 3.1.2.11 Beta-Thalassaemia
    - 3.1.2.12 Inheritance Pattern of Autosomal Recessive Genetic Disorders
    - 3.1.2.13 Chances of Inheriting a Single Gene Disorder
    - 3.1.2.14 Common Recessive Disease Traits in Selected Ethnic Groups
    - 3.1.2.15 Comprehensive List of Common Single Gene Disorders



- 3.1.3 X-Linked Dominant Genetic Disorders
  - 3.1.3.1 Hypophosphotemic Rickets
  - 3.1.3.2 Incontinentia Pigmenti
  - 3.1.3.3 Focal Dermal Hypoplasia
  - 3.1.3.4 Orofaciodigital Syndrome
  - 3.1.3.5 Inheritance of Sex-Linked Dominant Disorders
- 3.1.4 X-Linked Recessive Disorders
  - 3.1.4.1 Lesch-Nyhan Syndrome
  - 3.1.4.2 Menkes Disease (Kinky hair syndrome)
  - 3.1.4.3 Hemophilia A and B
  - 3.1.4.4 Fabry's Disease
  - 3.1.4.5 Wiskott-Aldrich syndrome (WAS)
  - 3.1.4.6 Bruton's Aggamaglobulinemia
  - 3.1.4.7 Color Blindness
  - 3.1.4.8 Complete Androgen Insensitivity Syndrome
  - 3.1.4.9 Inheritance of X-Linked Recessive Traits
- 3.2 Chromosomal Disorders
  - 3.2.1 47, XXY (Klinefelter Syndrome)
    - 3.2.1.1 Prenatal Diagnosis of Klinefelter Syndrome
  - 3.2.2 47, XYY Syndrome
    - 3.2.2.1 Diagnosis of 47, XYY Syndrome
  - 3.2.3 45, X Syndrome (Turner Syndrome)
    - 3.2.3.1 Prenatal Diagnosis of Turner Syndrome
  - 3.2.4 47, XXX (Triple X Syndrome)
    - 3.2.4.1 Tests for Triple X Syndrome
  - 3.2.5 Trisomy 21 (Down Syndrome)
    - 3.2.5.1 Tests for Down Syndrome
    - 3.2.5.2 Incidence of Down Syndrome by Maternal Age
    - 3.2.5.3 Developmental Delay in Children with Down Syndrome
  - 3.2.6 Trisomy 18 (Edward's Syndrome)
    - 3.2.6.1 Prenatal Diagnosis of Trisomy
    - 3.2.6.2 Clinical Manifestations of Trisomy
  - 3.2.7 Trisomy 13 (Patau Syndrome)
    - 3.2.7.1 Prenatal Diagnosis of Trisomy
  - 3.2.8 Triploid Syndrome
    - 3.2.8.1 Congenital Anomalies Associated with Triploidy
    - 3.2.8.2 Prenatal Diagnosis of Triploidy
  - 3.2.9 Prevalence of Trisomies in the U.S.
    - 3.2.9.1 Trisomies and Abortions

- 3.2.10 Maternal Age-Related Frequencies of Aneuploid Fetuses
- 3.2.11 Clinical Features of Common Chromosomal Aneuploidy
- 3.2.12 Maternal Age and Chromosomal Aneuploidy
- 3.2.13 Sensitivity and Specificity of Maternal Serum and Ultrasound Tests for Aneuploids
- 3.3 Structural Chromosomal Abnormalities
  - 3.3.1 Autosomal Deletions
    - 3.3.1.1 Wolf-Hirschhorn Syndrome (WHS)
    - 3.3.1.2 Cri du chat Syndrome
    - 3.3.1.3 Langer-Giedion Syndrome
  - 3.3.2 Common Autosomal Microdeletion Syndrome
    - 3.3.2.1 Williams Syndrome
    - 3.3.2.2 WAGR Syndrome
    - 3.3.2.3 Prader-Willi Syndrome (PWS)
    - 3.3.2.4 Angelman Syndrome
    - 3.3.2.5 Miller-Dieker Syndrome
    - 3.3.2.6 Smith-Magenis Syndrome (SMS)
    - 3.3.2.7 Alagille Syndrome (ALGS)
    - 3.3.2.8 CATCH 22 Syndrome
    - 3.3.2.9 DiGeorge Syndrome
  - 3.3.3 Autosomal Duplication Syndromes
    - 3.3.3.1 Beckwith-Wiedemann Syndrome (BWS)
    - 3.3.3.2 Charcot-Marie-Tooth Disease Type 1A (CMT1A)
    - 3.3.3.3 Cat-Eye Syndrome
  - 3.3.4 Appropriate Technologies for the Detection of Microdeletions, Duplications and Copy Number Variants

#### **4. GENETIC COUNSELLING: AN OVERVIEW**

- 4.1 Impact of Recent Advances in Clinical Genomics on Genetic Counselling
- 4.2 Genetic Counsellors in DTC GT Industry
  - 4.2.1 Types of Genetic Counselling Offered by DTC GT Companies
  - 4.2.2 Roles of Genetic Counsellors in DTC GT Industry

#### **5. PRENATAL SCREENING FOR GENETIC DISEASES: AN OVERVIEW**

- 5.1 Routine Prenatal Screening Tests
- 5.2 Less-Routine Prenatal Screening Tests
- 5.3 Beta Human Chorionic Gonadotropin (?-hCG) Screening Test

- 5.3.1 hCG Kits and Manufacturers
- 5.4 First Trimester Pregnancy-Associated Plasma Protein-A (PAPP-A) Screening Test
- 5.5 Maternal Serum Alpha-Fetoprotein (MSAFP) Screening Test
- 5.6 Second Trimester Serum  $\alpha$ -hCG Screening Test
- 5.7 Second Trimester Unconjugated Estriol (uE3) Screening Test
- 5.8 Second Trimester Inhibin-A Screening Test
- 5.9 Second Trimester Hexosaminidase Test
- 5.10 Second Trimester Triple-Screen Quad Screen Tests
- 5.11 Second Trimester Screening of Cell-Free Fetal DNA (cffDNA)
  - 5.11.1 Sensitivity and Specificity of NIPTs
  - 5.11.2 Diagnostic Applications of cffDNA
  - 5.11.3 Time of Availability of cffDNA in Maternal Blood
  - 5.11.4 The Cost of NIPTs
  - 5.11.5 Cost of NIPTs by Product
  - 5.11.6 History of Aneuploidy Testing from 1970s to 2011
  - 5.11.7 NIPT Methods of Detecting Aneuploidy
    - 5.11.7.1 Shotgun Method
    - 5.11.7.2 Targeted Massively Parallel Sequencing (t-MPS)
    - 5.11.7.3 Single Nucleotide Polymorphisms (SNPs)
  - 5.11.8 Comparison of Amniocentesis and NIPT
  - 5.11.9 Advantages of NIPTs
  - 5.11.10 Disadvantages of NIPTs
  - 5.11.11 Comparison of Performance Criteria for Commonly used Prenatal Tests
  - 5.11.12 Comparison of NIPT Detection Rates with Traditional Tests
  - 5.11.13 False Positive Rates of NIPTs Compared with Those of Traditional Tests
  - 5.11.14 Fetal Genetic Disorders Detected by NIPTs and other Screening Tests
- 5.12 First Trimester Ultrasound Screening Test
  - 5.12.1 Nuchal Translucency (NT) Screening Test
- 5.13 Magnetic Resonance Imaging (MRI) in Prenatal Screening
- 5.14 Prenatal Diagnosis of Genetic Disorders
  - 5.14.1 Amniocentesis (AC)
    - 5.14.1.1 Reliability of Amniocentesis
  - 5.14.2 Chorionic Villus Sampling (CVS)
    - 5.14.2.1 Reliability of CVS Test
  - 5.14.3 Cordocentesis or Percutaneous Umbilical Blood Sampling
- 5.15 Advantages and Disadvantages of Prenatal Diagnostic Tests
- 5.16 Future of Invasive Prenatal Diagnostic Tests
  - 5.16.1 Indispensability of Invasive Diagnostic Tests
- 5.17 Intact Circulating Fetal Cells for Noninvasive Prenatal Tests

- 5.17.1 Scheme for Isolating Intact Fetal Cells from Maternal Blood
- 5.18 Trophoblast Retrieval and Isolation from Cervix (TRIC)

## **6. NEWBORN SCREENING**

- 6.1 Status of Newborn Screening in Developed and Developing Countries
- 6.2 Status of Newborn Screening in Middle East and North Africa (MENA)
- 6.3 Screening Tests Recommended for Newborns in the U.S.
- 6.4 Most Common Newborn Genetic Disorders
  - 6.4.1 Phenylketonuria (PKU)
    - 6.4.1.1 Screening Tests Used for Diagnosis of PKU
  - 6.4.2 Congenital Hypothyroidism (CHT)
    - 6.4.2.1 Inheritance of CHT
    - 6.4.2.2 Signs and Symptoms of CHC
    - 6.4.2.3 Diagnosis of CHT
  - 6.4.3 Congenital Adrenal Hyperplasia
    - 6.4.3.1 Inheritance of Congenital Adrenal Hyperplasia
    - 6.4.3.2 Symptoms of Congenital Adrenal Hyperplasia
    - 6.4.3.3 Diagnosis of Congenital Adrenal Hyperplasia
  - 6.4.4 Galactosemia
    - 6.4.4.1 Signs and Symptoms of Galactosemia
    - 6.4.4.2 Diagnosis of Galactosemia
  - 6.4.5 Sickle Cell Disease (SCD)
    - 6.4.5.1 Symptoms of SCD
    - 6.4.5.2 Diagnosis of SCD
  - 6.4.6 Biotinidase Deficiency
    - 6.4.6.1 Inheritance of Biotinidase Deficiency
    - 6.4.6.2 Signs and Symptoms of Biotinidase Deficiency
    - 6.4.6.3 Diagnosis of Biotinidase Deficiency
  - 6.4.7 Homocystinuria
    - 6.4.7.1 Signs and Symptoms of Homocystinuria
    - 6.4.7.2 Diagnosis of Homocystinuria
  - 6.4.8 Maple Syrup Urine Disease (MSUD)
    - 6.4.8.1 Inheritance of MSUD
    - 6.4.8.2 Diagnosis of MSUD

## **7. PREIMPLANTATION GENETIC SCREENING & GENETIC DIAGNOSIS (PGS/PGD)**

- 7.1 PGS/PGD Technologies

- 7.1.1 Fluorescent in situ Hybridization (FISH)
- 7.1.2 Array Comparative Genome Hybridization (aCGH)
- 7.1.3 Single Nucleotide Polymorphism (SNP) Microarray
- 7.1.4 Oligonucleotide Genome Sequencing (OGS)
- 7.1.5 Express Genome Sequencing (EGS)
- 7.1.6 Next Generation Sequencing (NGS)
- 7.2 Strengths and Weaknesses of Currently Available PGS/PGD Technologies
- 7.3 Genetic Diseases Detected During PGD
- 7.4 PGS/PGD Testing Products in the Market
- 7.5 Cost of in vitro Fertilization and Related Procedures

## **8. PREGNANCY, PRENATAL, NEWBORN AND PGD-RELATED TECHNOLOGIES: AN OVERVIEW**

- 8.1 Beta Human Chorionic Gonadotropin (?-hCG) Test
  - 8.1.1 Setting up the Test Strip
  - 8.1.2 Procedure of the Test
  - 8.1.3 Interpretation of ?-hCG Test Result
- 8.2 Pregnancy Associated Plasma Protein-A (PAPP-A) Test
  - 8.2.1 Principle of PAPP-A Test
- 8.3 Maternal Serum Alpha Fetoprotein (MSAFP) Test
  - 8.3.1 Principle of MSAFP Test
- 8.4 Unconjugated Estriol (uE3) Test
  - 8.4.1 Principle of uE3 Test
- 8.5 Inhibin A Test
  - 8.5.1 Principle of Inhibin A Test
- 8.6 Fetal Karyotyping
- 8.7 Extended Banding Chromosome Studies
- 8.8 Innovation in Invasive Prenatal Diagnosis
  - 8.8.1 Microarray: An Alternative for Karyotyping
  - 8.8.2 Rapid Aneuploid Detection by Quantitative Fluorescent PCR (QF-PCR)
    - 8.8.2.1 Principles of QF-PCR
  - 8.8.3 Fluorescence in situ Hybridization (FISH)
    - 8.8.3.1 The Format of Fish Test Result
    - 8.8.3.2 Commonly Used FISH-Based Tests
    - 8.8.3.3 Microdeletions/Microduplications Detectable by FISH
    - 8.8.3.4 Types of FISH Probes and Their Functions
  - 8.8.4 Microarray-Based Comparative Genomic Hybridization (array-CGH)
- 8.9 Advances in Prenatal Screening: The Power to Know Sooner

- 8.9.1 NIPTs: An Overview of Tests and Technologies
  - 8.9.1.1 Harmony Test
  - 8.9.1.2 InformaSeq
  - 8.9.1.3 Panorama Test
  - 8.9.1.4 Prena Test
  - 8.9.1.5 NIFTY Test
  - 8.9.1.6 IONA Test
  - 8.9.1.7 Verifi Test
  - 8.9.1.8 MaterniT GENOME Test
  - 8.9.1.9 MaterniT21 PLUS Test
  - 8.9.1.10 HeridiT UNIVERSAL Carrier Screen
- 8.9.2 Comparison of MaterniT21 PLUS, Verifi, Harmony and Panorama Tests
- 8.9.3 U.S. Patents for NIPTs by Company
  - 8.9.3.1 Selected Issued Patents of NIPTs
  - 8.9.3.2 Assignees of Major U.S. Patents and their Current Licensees
- 8.9.4 Global Availability of NIPTs
- 8.9.5 Cost Effectiveness of NIPTs
- 8.9.6 Clinical Implementation Strategies to be adopted for NIPTs
- 8.9.7 Integration of NIPT into Healthcare System: Patient-Directed Model
- 8.10 Tandem Mass Spectrometry (MS/MS) in Newborn Screening
- 8.11 Fetal Ultrasound in Prenatal Screening
  - 8.11.1 Types of Fetal Ultrasound Exams
  - 8.11.2 Best Obstetric and Gynecological Ultrasound Systems in the Market
  - 8.11.3 Best Premium Fetal Ultrasound Machines
    - 8.11.3.1 Philips Epiq 7
    - 8.11.3.2 GE Voluson E8
    - 8.11.3.3 GE Voluson E10
    - 8.11.3.4 Samsung UGEO WS80A
  - 8.11.4 High-End Systems
    - 8.11.4.1 Philips Epiq 5
    - 8.11.4.2 Philips Affinity 70
    - 8.11.4.3 GE Voluson E6
    - 8.11.4.4 GE Voluson S8
  - 8.11.5 Midrange Systems
    - 8.11.5.1 Philips Affinity 50
    - 8.11.5.2 GE Voluson S6
    - 8.11.5.3 Samsung AccuVix A30
    - 8.11.5.4 Philips Clear Vue 650
  - 8.11.6 Economy Systems

- 8.11.6.1 Philips Clear Vue 550
- 8.11.6.2 GE Logiq P5
- 8.11.6.3 Samsung H60
- 8.11.6.4 Alpinion Ecube 7
- 8.11.7 Portable Systems
  - 8.11.7.1 GE Voluson 1
  - 8.11.7.2 Samsung UGEO HM70A
- 8.12 Therapeutic Genome Editing: A Breakthrough Technology
  - 8.12.1 Genome Editing Technologies
    - 8.12.1.1 Growing Popularity of CRISPR Kits
  - 8.12.2 Therapeutic Applications of Genome Editing
  - 8.12.3 The First Genetically Modified Human Embryos

## **9. PRENATAL SCREENING AND DIAGNOSTICS: MARKET OVERVIEW**

- 9.1 Global Market for Fetal Ultrasound
  - 9.1.1 Market Leaders in Fetal Ultrasound
- 9.2 Global Market for Prenatal MRI Screening
- 9.3 Global Market for Maternal Serum Screening Tests
- 9.4 Global Market for Noninvasive Prenatal Tests (NIPTs) using cffDNA
  - 9.4.1 Global Market for NIPTs by Product
- 9.5 Global Market for Prenatal Diagnostic Invasive Tests
- 9.6 Global Market for Newborn Screening for Genetic Diseases
  - 9.6.1 Newborn Screening Market by Technology
- 9.7 Global Market for Preimplantation Screening/Diagnosis (PGS/PGD)

## **10. OTHER GENETIC TESTING-RELATED MARKETS**

- 10.1 Emerging Trends in Molecular Diagnostics Market
- 10.2 Emerging Trends in Liquid Biopsy Market
- 10.3 Emerging Trends in Personalized Medicine Diagnostics Market
- 10.4 Emerging Trends in in vitro Diagnostics (IVD) Market

## **11. MARKET SWOT AND STRATEGY ANALYSIS**

- 11.1 Acquisition Activities in Prenatal Screening Industry
  - 11.1.1 Acquisition of BlueGenome by Illumina
  - 11.1.2 Illumina's Acquisition of Verinata
  - 11.1.3 Eurofin's Joint Venture with Emory Genetics Laboratory



- 11.1.4 Roche's Acquisition of Ariosa Diagnostics
- 11.1.5 Cooper Surgical's Acquisition of Reprogenetics
- 11.2 Market Drivers
- 11.3 Market Restraints
- 11.4 Future of Prenatal Screening
- 11.5 Legislation Mandating Newborn Screening by Geography
  - 11.5.1 Newborn Screening Programs in Americas
  - 11.5.2 Newborn Screening Programs in Asia/Pacific
  - 11.5.3 Newborn Screening Programs in Europe
  - 11.5.4 Newborn Screening Programs in Middle East and Northern Africa
- 11.6 Ethical Voices against Problematic Applications of NIPT and NIPD
- 11.7 Clinical Implementation of NIPTs
  - 11.7.1 Implementation of NIPTs in Developed Countries
  - 11.7.3 Implementation of NIPTs in Developing and Under-Developed Countries
- 11.8 Adoption Rates for Different Prenatal Tests in the U.S.

## **12. COMPANY PROFILES**

- 12.1 23andMe Inc.
  - 12.1.1 23andMe's Agreement with Pfizer
  - 12.1.2 23andMe's Agreement with Genentech
  - 12.1.3 FDA's Approval for 23andMe's Screening Test for Bloom Syndrome
- 12.2 Abbott Laboratories
  - 12.2.1 ARCHITECT AFP Assay
- 12.3 Abbott Molecular Inc.
  - 12.3.1 AneuVysion
  - 12.3.2 Cystic Fibrosis Genotyping Assay
- 12.4 Abcam plc
  - 12.4.1 hCG Human ELISA Kit
- 12.5 AB Sciex LLC
- 12.6 Adaltis S.r.l.
  - 12.6.1 CLIAgen Free Beta-hCG Kit
- 12.7 Adaptive Biotechnologies Corp.
  - 12.7.1 ImmunoSEQ Platform
  - 12.7.2 ClonoSEQ
  - 12.7.3 Pipeline
    - 12.7.3.1 Quantifying Tumor Infiltration Lymphocytes in Solid Tumors
    - 12.7.3.2 Measuring Immune Reconstitution Post Transplant
    - 12.7.3.3 Diagnosing Cutaneous T-Cell Lymphoma (CTCL)



- 12.7.3.4 Therapeutics
- 12.8 Affymetrix Inc.
  - 12.8.1 Microarray Solutions
  - 12.8.2 Affymetrix's Collaborating Partners
  - 12.8.3 Affymetrix's R&D Investment
- 12.9 Agena Biosciences Inc.
  - 12.9.1 MassARRAY System
  - 12.9.2 Acquisition of Sequenom's Bioscience Business by Agena Biosciences
- 12.10 Agilent Technologies Inc.
  - 12.10.1 SureScan Microarray Scanner
  - 12.10.2 OneSeq
- 12.11 Ambry Genetics Corp.
  - 12.11.1 Clinical Diagnostic Tests
- 12.12 Analogic Corp.
  - 12.12.1 Flex Focus 500
  - 12.12.1 SonixTouchQ+
  - 12.12.3 SonixSP Q+
- 12.13 Ariosa Diagnostics Inc.
  - 12.13.1 Harmony Test
  - 12.13.2 Granting of Licenses to Harmony Test
- 12.14 Ansh Labs
  - 12.14.1 picoPAPP-A ELISA Kit
  - 12.14.2 Inhibin A ELISA Kit
- 12.15 Appistry Inc.
  - 12.15.1 GenomePilot
  - 11.15.2 Ayrris for NGS Analysis
  - 12.15.3 Variant Annotation and Analysis Suite
  - 12.15.4 CloudDx Translational
  - 12.15.5 CloudDx Clinical
  - 12.15.6 Appistry's Partnership with LifeMap Sciences
- 12.16 ARUP Laboratories
  - 12.16.1 Prenatal Screening and Diagnosis
  - 12.16.2 Next-Generation Sequencing (NGS)
  - 12.16.3 Noninvasive Prenatal Test for Aneuploids
- 12.17 AssureRx Health Inc.
  - 12.17.1 GeneSight Psychotropic
  - 12.17.2 GeneSight Analgesic
  - 12.17.3 GeneSight ADHD
  - 12.17.4 GeneSight MTHFR

- 12.18 Asuragen Inc.
  - 12.18.1 AmplideX FMR1 PCR
  - 12.18.2 AmplideX FMR1 mPCR
  - 12.18.3 AmplideX Controls
  - 12.18.4 Quantidex Pan Cancer Kit
  - 12.18.5 Quantidex BCR/ABL1 Quant Kit
  - 12.18.6 Quantidex DNA Assay
  - 12.18.7 Signature Technology
  - 12.18.8 Signature KRAS Mutations
  - 12.18.9 Signature BRAF Mutations
  - 12.18.10 Signature LTx v2.
  - 12.18.11 Signature NPM1 Mutations
- 12.19 Athena Diagnostics Inc.
- 12.20 AutoGenomics Inc.
  - 12.20.1 INFINITI System
- 12.21 Base4 Innovation Ltd.
  - 12.21.1 Microdroplet Sequencing
- 12.22 Beckman Coulter Inc.
  - 12.22.1 SPRiworks System I for Illumina Genome Analyzer
  - 12.22.2 SPRiworks HT for Illumina NGS Platform
  - 12.22.3 SPRiselect Reagent Kit
  - 12.22.4 Automated Sample Preparation
  - 12.22.5 Genomic Services
  - 12.22.6 Access Total Beta-hCG Reagent
  - 12.22.7 Access Inhibin A Assay
- 12.23 Berry Genomics Co., Ltd.
  - 12.23.1 Bambni Test
  - 12.23.2 Berry's Partnership with Illumina
- 12.24 Bina Technologies Inc.
  - 12.24.1 Bina RAVE
  - 12.24.2 Bina AAiM
  - 12.24.3 Bina's Collaboration with AsraZeneca
- 12.25 Bio-Rad (Israel) Laboratories Inc.
- 12.26 BGI
- 12.27 Blueprint Genetics Oy
  - 12.27.1 Services
- 12.28 Boreal Genomics Inc.
  - 12.28.1 OnTarget Mutation Detection System
  - 12.28.2 Aurora Platform

- 12.29 Cambridge Epigenetix Ltd.
  - 12.29.1 TrueMethyl Seq Kit
  - 12.29.2 TrueMethyl Array
- 12.30 Caris Lifesciences
  - 12.30.1 ADAPT Biotargeting System
  - 12.30.2 Caris Molecular Intelligence
  - 12.30.3 Collaboration between Caris Lifesciences and Syapse
- 12.31 CeGaT GmbH
  - 12.31.1 NGS Service
  - 12.31.2 ADME Research Panel
  - 12.31.3 Forschungsexom
- 12.32 Centogene AG
- 12.33 Chromsystems Instruments & Chemicals GmbH
- 12.34 Chronix Biomedical Inc.
  - 12.34.1 Technology
- 12.35 Claritas Genomics Inc.
- 12.36 CLC bio A/S
  - 12.36.1 Products
- 12.37 Combimatrix Corp.
  - 12.37.1 CombiSNP Array for Prenatal Diagnosis
  - 12.37.2 CombiPGS
- 12.38 Contec Medical Systems Co., Ltd.
  - 12.38.1 CMS600P B-Ultrasound Diagnostic System
  - 12.38.2 CMS600B3 B-Ultrasound Diagnostic System
- 12.39 Coriell Life Sciences Inc.
  - 12.39.1 GeneDose
- 12.40 Correlagen Diagnostics Inc.
- 12.41 Counsyl Inc.
  - 12.41.1 Family Prep Screen
  - 12.41.2 Informed Pregnancy Screen
  - 12.41.3 Inherited Cancer Screen
- 12.42 Courtagen Life Sciences Inc.
- 12.43 Creative Diagnostics
  - 12.43.1 Alpha-Fetoprotein, AFP ELISA Kit
  - 12.43.2 hCG ELISA Kit
  - 12.43.3 Human Free Estriol ELISA Kit
- 12.44 Cynvenio Biosystems Inc.
  - 12.44.1 LiquidBiopsy
  - 12.44.2 ClearID

- 12.44.3 Thermo Fisher's Distribution Agreement with Crynvenio
- 12.44.4 Cynvenio's Collaboration with the University of Southern Denmark
- 12.45 Diagnostic Automation/Cortez Diagnostics Inc.
- 12.46 Demeditec Diagnostics GmbH
  - 12.46.1 Estriol, Free/Uncojugated ELISA
- 12.47 DRG International Inc.
  - 12.47.1 DRG PAPP-A ELISA
- 12.48 DNA Electronics Ltd.
  - 12.48.1 Genalysis
- 12.49 DNA Link Inc.
  - 12.49.1 Services
  - 12.49.2 Partnership between Affymetrix and DNA Link Inc.
  - 12.49.3 DNAGPS
  - 12.49.4 AccuID
- 12.50 DNAnexus Inc.
  - 12.50.1 Adoption of DNAnexus' Cloud Genomics Platform by Natera
- 12.51 Eagle Biosciences Inc.
  - 12.51.1 Alport Syndrome Kit
  - 12.51.2 Free Beta-hCG ELISA
- 12.52 Eagle Genomics Ltd.
  - 12.52.1 EagleCore
  - 12.52.2 EagleNsembl
- 12.53 Enzymatics Inc.
  - 12.53.1 Reagents
  - 12.53.2 SPARK DNA Sample Preparation Kit
- 12.54 Esoate SpA
  - 12.54.1 MyLabGamma
  - 12.54.2 MyLab GOLD Platform
  - 12.54.3 MyLab 50
  - 12.54.4 MyLab 40
  - 12.54.5 MyLab 25Gold
- 12.55 Eurofins MWG Operon Inc.
  - 12.55.1 Products and Services
- 12.56 Exiqon A/S
  - 12.56.1 Products and Services
- 12.57 Fakuda Denshi Co., Ltd.
  - 12.57.1 UF-400AX
  - 12.57.2 UF-550XTD
  - 12.57.3 UF-760AG

- 12.57.4 UF-870AG
- 12.58 GATC Biotech AG
  - 12.58.1 Sanger Sequencing
- 12.59 GE Healthcare Ltd.
  - 12.59.1 VScan
  - 12.59.2 VScan with Dual Probe
  - 12.59.3 Logiq P5
  - 12.59.4 Logiq P6
  - 12.59.5 GE Venue 50
  - 12.59.6 GE Venue 40
  - 12.59.7 Logiq S8
  - 12.59.8 Logiq E9
- 12.60 GenapSys Inc.
  - 12.60.1 GENIUS
- 12.61 Gene by Gene Ltd.
- 12.62 Genection Inc.
- 12.63 GeneDx Inc.
  - 12.63.1 Cytogenetics and Biochemical Tests
  - 12.63.2 Deletion/Duplication Analysis
  - 12.63.3 Carrier Mutation-Specific Testing
- 12.64 GenePeeks Inc.
  - 12.64.1 Matchright Technology
- 12.65 Genesis Genetics
  - 12.65.1 GeniSeq24
  - 12.65.2 UltraPGD
  - 12.65.3 ArrayCGH
- 12.66 Genetadi Biotech S.L.
  - 12.66.1 AMNIOCHIP
  - 12.66.2 FERTICHIP
  - 12.66.3 PRENATAL GENE
- 12.67 Genoma Group Srl
- 12.68 Genomed AG
  - 12.68.1 Aneufast
- 12.69 GenPath Diagnostics
  - 12.69.1 InheriGen, InheriGen Plus and InheriGen Tx
  - 12.69.2 Prenatal Tests
- 12.70 Genway Biotech Inc.
- 12.71 Good Start Genetics Inc.
  - 12.71.1 EmbryVu

- 12.72 Hitachi Medical Systems America Inc.
  - 12.72.1 Arietta 70
  - 12.72.2 ProSound Alpha 7
  - 12.72.3 Noblus
  - 12.72.4 ProSound F37
- 12.73 Hologic Inc.
  - 12.73.1 InPlex CF Molecular Test
  - 12.73.2 Rapid fFN Test
- 12.74 Illumina Inc.
  - 12.74.1 The Verifi Prenatal Test
- 12.75 INEX Innovations Exchange Pte Ltd.
  - 12.75.1 iGene
  - 12.75.2 FlashFISH
  - 12.75.3 INEX's Collaborative Agreement with BGI
- 12.76 Invitae Corp.
- 12.77 Laboratory Corporation of America Inc.
  - 12.77.1 Services
- 12.78 LifeCodexx AG
  - 12.78.1 Prena Test
- 12.79 Monobind Inc.
  - 12.79.1 Fertility VAST Panel: HCG, FSH, LH, SPRL
  - 12.79.2 PAPP-A Test
- 12.80 Multiplicom NV
  - 12.80.1 Clarigo
- 12.81 Myriad Genetics
- 12.82 Natera Inc.
  - 12.82.1 Panorama Prenatal Screen
    - 12.82.1.1 Accuracy of Panorama Test
    - 12.82.1.2 Minimal False Negatives in Panorama
  - 12.82.2 Horizon Carrier Screening
  - 12.82.3 Spectrum Preimplantation Test
  - 12.82.4 Natera's 24-chromosome PGS
  - 12.82.5 Anora Miscarriage Test
  - 12.82.6 Prenatal Paternity Test
  - 12.82.7 Agreement between Natera and LifeLabs
- 12.83 Natus Medical Inc.
  - 12.83.1 ABaer
  - 12.83.2 Algo 5
  - 12.83.3 Algo 3i

- 12.83.4 AuDX
- 12.83.5 Echo-Screen III
- 12.84 NewGene Ltd.
  - 12.84.1 Hereditary Disorders
  - 12.84.2 Alport Syndrome
  - 12.84.3 Aortopathy Panel
  - 12.84.4 RASopathy Gene Panel
  - 12.84.5 Familial Hypercholesterolaemia
- 12.85 NIPD Genetics Ltd.
  - 12.85.1 VERACITY Test (NIPT)
- 12.86 Oxford Gene Technology (OGT)
  - 12.86.1 SureSeq NGS Library Preparation Kit
  - 12.86.2 CytoSure Embryo Screen Array
  - 12.86.3 CytoSure FISH Probes
  - 12.86.4 CytoSure Embryo Screen Array
  - 12.86.5 CytoSure Aneuploidy Array
  - 12.86.6 CytoSure Chromosome X Arrays
- 12.87 Parabase Genomics Inc.
  - 12.87.1 NewbornDx Test
- 12.88 Pathway Genomics Corp.
  - 12.88.1 Carrier Screening
- 12.89 PerkinElmer Life and Analytical Sciences Inc.
  - 12.89.1 DELFIA Xpress PIGF Assay
  - 12.89.2 DELFIA Xpress PAPP-A Kit
  - 12.89.3 AutoDELFIA PAPP-A Kit
  - 12.89.4 StepOne Newborn Screens
- 12.90 Premaitha Health PLC
  - 12.90.1 IONA Test
  - 12.90.2 Premaitha's Investment Agreement with Thermo Fisher
- 12.91 Progenity Inc.
  - 12.91.1 nxtPanel Test
  - 12.91.2 Verifi Test
  - 12.91.3 Acquisition of Carmenta Bioscience by Progenity
- 12.92 Qiagen N.V.
  - 12.92.1 Next-Generation Sequencing (NGS)
  - 12.92.2 Target Enrichment Solutions
  - 12.92.3 Library Construction
- 12.93 Quest Diagnostics Inc.
  - 12.93.1 QNatal Advanced

- 12.93.2 Inhibin A
- 12.94 Ravgen Inc.
  - 12.94.1 Prenatal Downs Syndrome Testing
  - 12.94.2 Single Gene Disorder Testing
- 12.95 Recombine Inc.
  - 12.95.1 CarrierMap
- 12.96 Reproductive Genetics Institute Inc.
- 12.97 Reprogenetics Laboratories
  - 12.97.1 Array CGH (aCGH)
  - 12.97.2 Single Gene Disorder Testing
  - 12.97.3 WaferGen Biosystems' Supply Agreement with Reprogenetics
- 12.98 Sebia Inc.
- 12.99 Sequenom Inc.
  - 12.99.1 MaterniT GENOME Test
    - 12.99.1.1 Sensitivity and Specificity of MaterniT GENOME Test
  - 12.99.2 MaterniT21 PLUS
    - 12.99.2.1 Sensitivity and Specificity of MaterniT21 PLUS
  - 12.99.3 HerediT UNIVERSAL Carrier Screen
  - 12.99.4 VisibiliT Prenatal Test
  - 12.99.5 HerediT Cystic Fibrosis Carrier Screen
    - 12.99.5.1 Clinical Data for HerediT
  - 12.99.6 SensiGene Fetal RHD Genotyping
  - 12.99.7 NextView Prenatal Diagnostic Tests
- 12.100 SeraCare Life Sciences Inc.
  - 12.100.1 Seraseq Trisomy 21 Aneuploidy Reference Material
- 12.101 Siemens Healthcare
  - 12.101.1 Acuson S2000
  - 12.101.2 Acuson X700
  - 12.101.3 Acuson X600
  - 12.101.4 Acuson X300 PE
  - 12.101.5 Acuson X150
  - 12.101.6 Acuson Antares
  - 12.101.7 Acuson P300
- 12.102 Sophia Genetics SA
  - 12.102.1 Clinical Genomic Modules
- 12.103 SpOtOn Clinical Diagnostics Ltd.
  - 12.103.1 Newborn Screening
  - 12.103.2 Ante-Natal Testing
- 12.104 Stra Biotech GmbH



- 12.105 Sygnis AG
  - 12.105.1 TruePrime Single Cell WGA Kit
  - 12.105.2 TruePrime WGA Kit
  - 12.105.3 TruePrime RCA Kit
  - 12.105.4 SunScript Reverse Transcriptase RNaseH+ and RNaseH- Kits
  - 12.105.5 SensiPhi/QualiPhi
- 12.106 SynapDx Corporation
  - 12.106.1 ASD Diagnosis
- 12.107.1 Thermo Fisher's Brands
- 12.108 Transgenomic Inc.
  - 12.108.1 Technology Suite
  - 12.108.2 MX-ICP Technology
  - 12.108.3 ICEme Kit
  - 12.108.4 Other Products
- 12.109 Trivitron Healthcare Private Ltd.
- 12.110 Trovogene Inc.
  - 12.110.1 PCM BRAF V600E Mutation Detection Test
  - 12.110.2 PCM KRAS Mutation Detection Test
  - 12.110.3 PCR EGFR Mutation Detection Test
  - 12.110.4 HPV HR Detection Test
- 12.111 Tute Genomics Inc.
  - 12.111.1 Tute Platform
- 12.112 Warp Drive Bio LLC
  - 12.112.1 Wrap's New Approach
  - 12.112.2 Chemomemes
  - 12.112.3 Genomic Search Engine
- 12.113 ZS Genetics Inc.
  - 12.113.1 3G Sequencing
- 12.114 Zymo Research Corporation
  - 12.114.1 DNA Methylation Products
    - 12.114.1.1 Bisulfite Conversion
    - 12.114.1.2 Methylated DNA Standards
    - 12.114.1.3 DNA Methyltransferases
    - 12.114.1.4 5-mC ELISA
    - 12.114.1.5 5-mC Antibodies and Immunoprecipitation
    - 11.114.1.6 Region-Specific DNA Methylation Analysis
    - 12.114.1.7 Global 5-mC Quantification
    - 12.114.1.8 Genome-wide 5-mC Analysis
  - 12.114.2 DNA Purification Products

- 12.114.2.1 DNA Clean-up
- 12.114.2.2 Plasmid DNA Purification
- 12.114.2.3 Genomic DNA
- 12.114.2.4 Microbial and Environmental DNA Isolation
- 12.114.2.5 DNA/RNA Co-Purification
- 12.114.2.6 Sample Collection and Stabilization
- 12.114.2.7 DNA Ladders
- 12.114.2.8 Enzymes
- 12.114.2.9 High-Throughput/Automated Isolation
- 12.114.2.10 DNA Analysis Kits
- 12.114.3 Other Products

## **APPENDIX**

Appendix 1: Representative Companies in Prenatal and Maternal Diagnostics and their Products

Appendix 2: Sources for Tables and Graphs

## Index Of Figures

### INDEX OF FIGURES

Figure 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021

Figure 2.1: Risk of Down Syndrome and Chromosomal Abnormalities Due to AMA

Figure 2.2: Maternal Age and Pregnancy Loss Rate

Figure 2.3: Risk of Cesarean Section with Increasing AMA

Figure 2.4: Risk of Gestational Diabetes with AMA

Figure 2.5: Risk of Placenta Previa with AMA

Figure 2.6: Delayed First Pregnancy in the U.S.

Figure 2.7: First Birth Rates for 35-39 Aged U.S. Women by Race

Figure 2.8: Pre-Existing Chronic Diseases among Women of Reproductive Ages in the U.S.

Figure 2.9: Chronic Disease Risk Behaviors and Risk Factors among Women of Reproductive Ages in the U.S.

Figure 2.10: Prevalence of Preeclampsia during Pregnancy by Race/Ethnicity in the U.S.

Figure 2.11: Prevalence of Preeclampsia by Maternal Age in the U.S.

Figure 2.12: Prevalence of Gestational Diabetes by Maternal Age in the U.S.

Figure 2.13: Prevalence of Gestational Diabetes by Maternal Race/Ethnicity in the U.S.

Figure 2.14: Causes of Preterm Labor

Figure 2.15: Prevalence of Preterm Births in the U.S. by Stage

Figure 2.16: Prevalence of Preterm Births in the U.S. by Race/Ethnicity

Figure 2.17: Prevalence of Preterm Births in the U.S. by Plurality of Birth

Figure 2.18: Prevalence of Preterm Births in the U.S. by Maternal Age

Figure 2.19: Prevalence of Multiple Births in the U.S.

Figure 3.1: Inheritance of Autosomal Dominant Faulty Gene When One Parent is a Carrier

Figure 3.2: Inheritance of Autosomal Dominant Faulty Gene When Both Parents are Carriers

Figure 3.3: Percent of Patients taking Sweat Chloride Test Reported in the U.S. Registry

Figure 3.4: Age at CF Diagnosis for all People Reported in the U.S. Registry, 2013

Figure 3.5: Distribution of Race/Ethnicity among People with CS in the U.S., 2013

Figure 3.6: Percent of New CF Diagnosis in U.S. Newborn Screenings, 1990-2013

Figure 3.7: The Six Most Common CFTR Mutations in the U.S.

Figure 3.8: Autosomal Recessive Inheritance when Both Parents are Carriers

Figure 3.9: Autosomal Recessive Inheritance with Carrier Mother and Non-Carrier Father

Figure 3.10: Autosomal Recessive Inheritance from Homozygous Recessive Mother and Carrier Father

Figure 3.11: Autosomal Recessive Inheritance from Two Affected Parents

Figure 3.12: Inheritance Pattern of Sex-Linked Dominant Disorder with Affected Mother and Carrier Father

Figure 3.13: X-Linked Recessive Inheritance with a Carrier Mother and Non-Carrier Father

Figure 3.14: X-Linked Recessive Inheritance with Normal Mother and Affected Father

Figure 3.15: Incidence of Down Syndrome by Maternal Age in the U.S.

Figure 3.16: Prevalence of Trisomies in the U.S.

Figure 3.17: Relative Frequencies of Chromosomal Anomalies in Spontaneous Abortions

Figure 3.18: Maternal Age and Chromosomal Aneuploidy Detected at Amniocentesis

Figure 5.1: Genetic Disorders (%) Detectable by Prenatal Testing Methods

Figure 5.2: Nuchal Translucency as Seen in an Ultrasound Scan

Figure 5.3: The Amniocentesis Procedure

Figure 5.4: Chorionic Villus Sampling Procedure

Figure 5.5: Transvaginal CVS Procedure

Figure 5.6: Decline in Number of Amniocentesis at Yale New Haven Hospital and Bridgeport Hospital in the U.S. between 2011 and 2013

Figure 5.6: Scheme for Isolating Intact Fetal Cells for Prenatal Genetic Diagnosis

Figure 6.1: Number of Newborn Genetic Diseases Screened in Selected Countries

Figure 6.2: The Top Four Countries with Homocystinuria Population (per 100,000)

Figure 7.1: Indications for PGD

Figure 8.1: Markings on the Test Strip

Figure 8.2: Procedure of  $\alpha$ -hCG Test

Figure 8.3: Interpretation of  $\alpha$ -hCG Test Result

Figure 8.4: Fetal Karyotype Showing Trisomy 21 (Down Syndrome)

Figure 8.5: Peak Heights Indicating Aneuploidy in QF-PCR Study

Figure 8.6: Diagrammatic Representation of Steps Involved in FISH Test

Figure 8.7: FISH Test Showing Chromosomal Deletion

Figure 8.8: Steps Involved in Array-CGH

Figure 8.9: History of Innovations in NIPTs from 2011-2015

Figure 8.10: Detection Rate of Harmony Test Compared with Traditional Maternal Serum Tests

Figure 8.11: Global Availability of NIPTs

Figure 8.12: Preference of NIPTs by Pregnant Women at Santa Clara Valley Medical

Center

Figure 8.13: Patient-Directed Model of Integrating NIPTs into Healthcare Setting

Figure 8.14: Growing Popularity of CRISPR-Cas9 Kits

Figure 9.1: Ultrasound Imaging Market Share (%) by Clinical Application

Figure 9.2: Global Market for Fetal Ultrasound Screening by Geography (U.S., Europe, RoW), Through 2021

Figure 9.3: Global Fetal Ultrasound Market Share by Company, 2014

Figure 9.4: Global Market for MRI Prenatal Screening by Geography (U.S., Europe, RoW), Through 2021

Figure 9.5: Global Market for Maternal Serum Screening Tests by Geography (U.S., Europe, RoW), Through 2021

Figure 9.6: Share of NIPTs Market by Geography (North America, Europe, RoW)

Figure 9.7: Global Market for NIPTs by Geography (North America, Europe, RoW), Through 2021

Figure 9.8: Global Market for NIPTs by Product

Figure 9.9: Global Market for Prenatal Invasive Diagnostic Tests by Geography (U.S., Europe, RoW), Through 2021

Figure 9.10: Global Market for Newborn Screening, Through 2021

Figure 9.11: Global Market for Newborn Screening by Technology, Through 2021

Figure 9.12: Global Market for MS/MS in Newborn Screening, Through 2021

Figure 9.13: Global Market for Pulse Oximetry in Newborn Screening, Through 2021

Figure 9.14: Global Market for Enzyme-Based Assays in Newborn Screening, Through 2021

Figure 9.15: Global Market for DNA Assays in Newborn Screening, Through 2021

Figure 9.16: Global Market for Electrophoresis in Newborn Screening, Through 2021

Figure 9.17: Geographical Share of PGS/PGD Market

Figure 9.18: Global Market for PGS/PGD by Geography (North America, Europe, RoW)

Figure 10.1: Global Market for Molecular Diagnostics, Through 2021

Figure 10.2: Global Market for Liquid Biopsy by Geography (North America, Europe, RoW), Through 2021

Table 10.3: Global Market for Personalized Medicine by Business Segment, Through 2021

Figure 10.4: Percent Share of IVD Market by Business Segments

Figure 10.5: Global IVD Market by Geography (North America, Europe, RoW), Through 2021

Figure 12.1: Comparison of False Negative Rates

Figure 12.2: Sensitivity and Specificity of MaterniT GENOME Test

## Index Of Tables

### INDEX OF TABLES

Table 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021

Table 2.1: Risk of Down Syndrome and Chromosomal Abnormalities Due to AMA

Table 2.2: Maternal Age and Pregnancy Loss Rate

Table 2.3: Risk of Cesarean Section with Increasing AMA

Table 2.4: Risk of Gestational Diabetes with AMA

Table 2.5: Risk of Placenta Previa with AMA

Table 2.6: Delayed First Pregnancy in the U.S.

Table 2.7: First Birth Rates for 35-39 Aged U.S. Women by Race

Table 2.8: Maternal and Fetal Concerns due to Pre-Existing Maternal Medical Issues

Table 2.9: Pregnancy Outcome in Women with Renal Diseases

Table 2.10: Pregnancy Outcome in Women with Pre-Existing Thyroid Disease

Table 2.11: Risks Associated with Obesity in Pregnant Women

Table 2.12: Pregnancy Complications in Asthmatic Women

Table 2.13: Pregnancy Complications and Neonatal Outcome in Women with Epilepsy

Table 2.14: Maternal and Fetal Complications in Women with Autoimmune Diseases

Table 2.15: Complications due to Hemoglobinopathies in Pregnancy

Table 2.16: Prevalence of Gestational Diabetes in the U.S.

Table 2.17: Countries with Higher and Lower Rates of Preterm Births

Table 2.18: Prevalence of Preterm Births in the U.S. by Stage

Table 2.19: Prevalence of Preterm Births in the U.S. by Race/Ethnicity

Table 2.20: Prevalence of Preterm Births in the U.S. by Plurality of Birth

Table 2.21: Prevalence of Preterm Births in the U.S. by Maternal Age

Table 2.22: Related Complications of Placenta Previa

Table 2.23: Mode of Delivery for Breech Presentation

Table 2.24: Perinatal Outcome due to Meconium Stained Liquor

Table 2.25: Pregnancy Outcome due to Polyhydramnios

Table 2.26: Causes of Fetal Growth Restriction

Table 2.27: Prevalence of Congenital Cardiovascular Diseases in the U.S.

Table 3.1: Worldwide Prevalence of Huntington Disease by Selected Country

Table 3.2: Prevalence of 25 Most Common CFTR Mutations in the U.S., 2013

Table 3.3: Molecular Diagnostic Tests for Canavan Disease

Table 3.4: Incidence of Sickle Cell Disease in the U.S.

Table 3.5: Red Blood Cell Indices in Beta-Thalassaemia

Table 3.6: Molecular Genetic Tests for Beta-Thalassaemia



Table 3.7: Chances of Inheriting a Single Gene Disorder

Table 3.8: More Common Recessive Disease Traits in Selected Ethnic Groups

Table 3.9: A Comprehensive List of Genetic Disorders

Table 3.10: Turnaround Time and Average Cost for Hemophilia Genetic Tests

Table 3.11: Incidence of Chromosomal Abnormalities

Table 3.12: Karyotypes Commonly Associated with Klinefelter Syndrome

Table 3.13: Features of Turner Syndrome in Different Age Groups

Table 3.14: Some Complications of Trisomy 21 (Down Syndrome)

Table 3.15: Incidence of Down Syndrome by Maternal Age

Table 3.16: Developmental Delay in Children with Down Syndrome

Table 3.17: Frequently Observed Anomalies in Babies with Trisomy 18

Table 3.18: Common Clinical Features of Trisomy 13

Table 3.19: Congenital Anomalies Associated with Triploidy

Table 3.20: Relative Frequencies of Different Chromosomal Anomalies in Spontaneous Abortions

Table 3.21: Maternal Age-Related Frequencies of Aneuploid Fetuses Detected Prenatally

Table 3.22: Clinical Features of Common Chromosomal Aneuploidy

Table 3.23: Maternal Age and Chromosomal Aneuploidy

Table 3.24: Sensitivity and Specificity of Maternal Serum and Ultrasound Tests for Aneuploids

Table 3.25: Common Autosomal Deletions, Resulting Syndromes and Clinical Features

Table 3.26: Common Autosomal Microdeletion Syndromes

Table 3.27: Commonly Encountered Problems in Prader-Willi Syndrome

Table 3.28: Tests for Prader-Willi Syndrome

Table 3.29: Molecular Genetic Tests for CATCH 22 Syndrome

Table 3.30: Autosomal Duplication Syndromes

Table 3.31: Molecular Genetic Tests for Beckwith-Wiedemann Syndrome

Table 3.32: Molecular Diagnostic Tests for CMT1A

Table 4.1: Genetic Counseling Services by DTC GT Companies

Table 4.2: A List of Genetic Counseling Companies and Their Websites

Table 5.1: Major Prenatal Screening Tests during the First and Second Trimesters

Table 5.2: Other Routine and Non-Routine Prenatal Screening Tests

Table 5.3: hCG Levels from Date of Conception to 40th Week

Table 5.4: Selected  $\beta$ -hCG Kits and Manufacturers

Table 5.5: Selected PAPP-A Kits and Manufacturers

Table 5.6: Selected MSAFP Test Kits and Manufacturers

Table 5.7: Selected uE3 Test Kits and Manufacturers

Table 5.8: Selected Inhibin-A Test Kits and Manufacturers

Table 5.9: Selected Hexosaminidase Test Kits and Manufacturers

Table 5.10: Comparison of the Four Maternal Serum Screening Analyte Patterns

Table 5.11: The Five Popular Commercially Available Noninvasive Prenatal Tests (NIPTs)

Table 5.12: Sensitivity and Specificity of NIPTs

Table 5.13: Diagnostic Applications of cffDNA

Table 5.14: Time of Availability of cffDNA in Maternal Blood

Table 5.15: The Costs of NIPTs by Region/Country

Table 5.16: Costs of NIPTs by Product in the U.S.

Table 5.17: History of Aneuploidy Screening

Table 5.18: NIPT Methods for Detecting Aneuploidy

Table 5.19: Comparison of Amniocentesis and NIPTs

Table 5.20: Advantages and Disadvantages of NIPTs

Table 5.21: Comparison of Performance Criteria for Commonly Used Prenatal Tests

Table 5.22: Comparison of NIPT Detection Rates with Traditional Tests

Table 5.23: False Positive Rates of NIPTs Compared with those of Traditional Tests

Table 5.24: Different Applications of Ultrasound in Different Trimesters

Table 5.25: MRI Indications for Prenatal Screening when Ultrasound Screening is Inadequate

Table 5.26: Prenatal Diagnostic Tests by Pregnancy Stage

Table 5.27: Comparison of CVS and Amniocentesis

Table 5.28: Advantages and Disadvantages of Prenatal Diagnostic Tests

Table 5.29: Comparison of Prenatal Tests using Cell-Free Fetal DNA (cffDNA) and Intact Fetal Cells from Maternal Blood

Table 6.1: Thirty One Core Conditions Detected During Newborn Screening

Table 6.2: Categories of Newborn Genetic Disorders

Table 6.3: Metabolic Genetic Disorders Detectable by MS/MS and their Scores

Table 6.4: Incidence of PKU by Region

Table 6.5: Molecular Genetic Tests for Biotinidase Deficiency

Table 7.1: Advantages and Disadvantages of Currently Available PGS/PGD Technologies

Table 7.2: Genetic Diseases Detected During PGS/PGD

Table 7.3: Currently Available Products for PGS/PGD

Table 7.4: Cost of in vitro Fertilization and Related Procedures

Table 8.1: Karyotype vs. Microarray

Table 8.2: The Format of FISH Test Result

Table 8.3: Some Commonly Used FISH-Based Tests

Table 8.4: Microdeletions/Microduplications Detectable by FISH

Table 8.5: FISH Probes and Functions



Table 8.6: Presentation Format of Array-CGH Test Report

Table 8.7: Harmony vs. Traditional Down Syndrome Tests

Table 8.8: Predictive Value, Sensitivity and Specificity of InformaSeq Test

Table 8.9: Detection Rates of Panorama Test

Table 8.10: NIFTY Test Options

Table 8.11: Clinical Data for IONA Test

Table 8.12: Sensitivity and Specificity of Verifi Test

Table 8.13: Sensitivity and Specificity of Verifi's Microdeletion Panel

Table 8.14: Comparison of MaterniT GENOME Test and Karyotype

Table 8.15: Sensitivity and Specificity of MaterniT GENOME Test

Table 8.16: MaterniT21 PLUS' Independent Validation

Table 8.17: The Three Panels Offered by HeridiT UNIVERSAL Carrier Screen

Table 8.18: Comparison of the Four Major NIPT Products available in the U.S. Market

Table 8.19: U.S. Patents for NIPTs by Company

Table 8.20: Selected Issued Patents of NIPTs

Table 8.21: Major U.S. Patents and Applications

Table 8.22: Countries in Which NIPT is currently Marketed

Table 8.23: Detection, Uptake, False Positive and Failure Rates for NIPTs

Table 8.24: Cost of Different Prenatal Screens

Table 8.25: Disease Types Targeted by Different Nuclease Platforms

Table 9.1: Global Market for Fetal Ultrasound Screenong by Geography (U.S., Europe, RoW), Through 2021

Table 9.2: Global Fetal Ultrasound Market Share by Company, 2014

Table 9.3: Global Market for MRI Prenatal Screening by Geography (U.S., Europe and RoW), Through 2021

Table 9.4: Global Market for Maternal Serum Screening Tests by Geography (U.S., Europe, RoW), Through 2021

Table 9.5: Global Market for NIPTs by Geography (North America, Europe, RoW), Through 2021

Table 9.6: Global Market for NIPTs by Product

Table 9.7: Global Market for Prenatal Invasive Diagnostic Tests by Geography (U.S., Europe, RoW), Through 2021

Table 9.8: Global Market for Newborn Screening by Technology, Through 2021

Table 9.9: Global Market for PGS/PGD by Geography (North America, Europe, RoW), Through 2021

Table 10.1: Global Market for Liquid Biopsy by Region (North America, Europe, RoW), Through 2021

Table 10.2: Global Market for Personalized Medicine by Business Segment, Throgh 2021

Table 10.3: Global IVD Market by Geography (North America, Europe, RoW), Through 2021

Table 11.1: Adoption Rates for Different Prenatal Tests in the U.S.

Table 12.1: Financial Data for Affymetrix

Table 12.2: Selected Financial Data for Agilent Technologies

Table 12.3: Comparison of Harmony and Other Traditional Tests

Table 12.4: CombiSNP Prenatal Targeted Array Disorder List

Table 12.5: Genetic Tests Offered by Correlagen by Gene and Disease

Table 12.6: GeneDx's Cytogenetics and Biochemical Tests

Table 12.7: Hologic's Financial Data

Table 12.8: Performance of Verifi Test

Table 12.9: Verifi Prenatal Test Lab Partners in the U.S.

Table 12.10: Illumina's Financial Data

Table 12.11: Comparison of Prenatal Test Performance

Table 12.12: Comparison of False Negative Rates

Table 12.13: A Small Sample of Diseases Screened by Horizon Test

Table 12.14: Natus Medical's Financial Data

Table 12.15: Clinical Data for IONA Test

Table 12.16: Sensitivity and Specificity of MaterniT GENOME Test

Table 12.17: Sequenom's Financial Data

Table 12.18: Sensitivity and Specificity of MaterniT21 PLUS Test

Table 12.19: Three Options Offered by HeridiT UNIVERSAL Carrier Screen

Table 12.20: Clinical Evaluation Performance of VisibiliT Prenatal Test

Table 12.21: CF Detection Rates for Standard and Expanded Panels

Table 12.22: Accuracy, Sensitivity and Specificity of SensiGene Fetal RHD

Table 12.23: NextView Diagnostic Test Platforms

Table 12.24: Trovogene's Financial Data

Table Ap. 1.1: Participating Companies and their Products and Services

## I would like to order

Product name: Global Prenatal & Maternal Diagnostic Market To 2020

Product link: <https://marketpublishers.com/r/GC135016CA4EN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC135016CA4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970